Trial Profile
GEMTUZUMAB OZOGAMICIN (MYLOTARG (REGISTERED)) EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS IN THE UNITED STATES WITH RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA WHO MAY BENEFIT FROM TREATMENT AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Anthracyclines; Arsenic trioxide; Cytarabine
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Expanded access
- Sponsors Pfizer
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 26 Jul 2018 Planned End Date changed from 22 May 2021 to 4 Dec 2017.
- 28 Jun 2018 Status changed from recruiting to completed.